ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 159 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2018. The put-call ratio across all filers is 1.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $179,000 | -94.9% | 1,572 | -93.9% | 0.06% | -92.8% |
| Q4 2020 | $3,541,000 | -14.8% | 25,582 | -49.4% | 0.87% | -29.5% |
| Q3 2020 | $4,157,000 | +73.8% | 50,582 | +65.4% | 1.23% | +54.2% |
| Q2 2020 | $2,392,000 | +17.3% | 30,582 | -33.4% | 0.80% | -6.8% |
| Q1 2020 | $2,040,000 | +8.2% | 45,922 | +4.1% | 0.86% | +29.3% |
| Q4 2019 | $1,885,000 | +0.5% | 44,133 | 0.0% | 0.66% | -7.3% |
| Q3 2019 | $1,876,000 | -16.4% | 44,133 | +22.0% | 0.72% | -13.0% |
| Q2 2019 | $2,244,000 | +41.6% | 36,165 | -4.5% | 0.82% | +17.1% |
| Q1 2019 | $1,585,000 | 0.0% | 37,858 | 0.0% | 0.70% | +3.7% |
| Q4 2018 | $1,585,000 | -30.9% | 37,858 | +31.7% | 0.68% | -14.0% |
| Q3 2018 | $2,295,000 | +11.4% | 28,746 | +6.2% | 0.79% | +3.3% |
| Q2 2018 | $2,061,000 | +26.4% | 27,074 | -15.4% | 0.76% | +13.6% |
| Q1 2018 | $1,631,000 | – | 31,991 | – | 0.67% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |